Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

NCT05993949 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05993949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 2, 2023
Completion date
June 30, 2040
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia